Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis

Nephrology Dialysis Transplantation

Volumn 24, Issue 12, 2009, Pages 3677-3686

  Fung, Maple M ^a   Chen, Yuqing ^b   Lipkowitz, Michael S ^c   Salem, Rany M ^a,d   Bhatnagar, Vibha ^a   Mahata, Manjula ^a   Nievergelt, Caroline M ^e   Rao, Fangwen ^a   Mahata, Sushil K ^a   Schork, Nicholas J ^d   Brophy, Victoria H ^f   O'Connor, Daniel T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PEKING UNIVERSITY   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

AASK; African Americans; Glomerular filtration rate; Kidney disease; Sympathetic nervous system

Indexed keywords

ARGININE; BETA 1 ADRENERGIC RECEPTOR; GLYCINE; SERINE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DIPLOIDY; DNA POLYMORPHISM; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HAPLOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; PRIORITY JOURNAL;

ADULT; AFRICAN AMERICANS; AGED; FEMALE; GENETIC VARIATION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEPHROSCLEROSIS; RECEPTORS, ADRENERGIC, BETA-1; YOUNG ADULT;

EID: 71049158810     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp471     Document Type: Article

References (65)

1. Freedman BI, Spray BJ, Tuttle AB et al. The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis 1993; 21: 387-393
2. Ferguson R, Grim CE, Opgenorth TJ. A familial risk of chronic renal failure among blacks on dialysis? J Clin Epidemiol 1988; 41: 1189-1196
3. Rahman M, Douglas JG, Wright JT Jr. Pathophysiology and treatment implications of hypertension in the African-American population. En-docrinol Metab Clin North Am 1997; 26: 125-144
4. Freedman BI, Hicks PJ, Bostrom MAet al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009; 75: 736-745
5. Salem RM, Cadman PE, Chen Y et al. Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol 2008; 19: 600-614
6. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348: 1134-1149
7. Mancia G, Grassi G, Giannattasio C et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34(Pt 2): 724-728
8. Converse RL Jr., Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918
9. Bristow MR, Ginsburg R, Minobe W et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982; 307: 205-211
10. Sandilands AJ, O'Shaughnessy KM. The functional significance of genetic variation within the beta-adrenoceptor. Br J Clin Pharmacol 2005; 60: 235-243
11. Johnson JA, Zineh I, Puckett BJ et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74: 44-52
12. Pacanowski MA, Gong Y, Cooper-Dehoff RM et al. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008; 84: 715-721
13. Forleo C, Resta N, Sorrentino S et al. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 2004; 117: 451-458
14. Hassan M, York KM, Li H et al. Association of beta1-adrenergic receptor genetic polymorphism with mental stress-induced myocardial ischemia in patients with coronary artery disease. Arch Intern Med 2008; 168: 763-770
15. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636
16. Sika M, Lewis J, Douglas J et al. Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study. Am J Kidney Dis 2007; 50: 78-89
17. Wright JT Jr., Kusek JW, Toto RD et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996; 17(4 Suppl): 3S-16S
18. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719-2728
19. Fogo A, Breyer JA, Smith MC et al. AASK Pilot Study Investigators. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. Kidney Int 1997; 51: 244-252
20. Wright JT Jr., Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431
21. Rathz DA, Gregory KN, Fang Y et al. Hierarchy of polymorphic variation and desensitization permutations relative to beta 1-and beta 2-adrenergic receptor signaling.J Biol Chem 2003; 278: 10784-10789
22. Hall WD, Kusek JW, Kirk KA et al. Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis 1997; 29: 720-728
23. Wright JT Jr., Agodoa L, Contreras G et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002; 162: 1636-1643
24. Salem RM, Fung MM, Pandey B et al. Electronic Medical Records in the Post-Genomic Era: The VA Hypertension Primary Care Longitudinal Cohort. Genetic Epidemiology. Forthcoming 2009
25. Brown SH, Lincoln MJ, Groen PJ et al. VistA-U.S. Department of Veterans Affairs National-Scale HIS. Int J Med Inform 2003; 69: 135-156
26. Levey AS, Bosch JP, Lewis JB et al. Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-470
27. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. Am J Kidney Dis 2009; 53(Suppl 3): S4-S16
28. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31
29. Cheng S, Grow MA, Pallaud C et al. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 1999; 9: 936-949
30. Hill W. Estimation of linkage disequilibrium in randomly mating populations. Heredity 1974; 33: 229-239
31. McKeigue PM, Carpenter JR, Parra EJ et al. Estimation of admixture and detection of linkage in admixed populations by a Bayesian approach: application to African-American populations. Ann Hum Genet 2000; 64(Pt 2): 171-186
32. Nievergelt CM, Libiger O, Schork NJ. Generalized analysis of molecular variance. PLoS Genet 2007; 3: e51
33. Littell RC, Milliken GA, Stroup WW et al. SAS for Mixed Models. 2nd edn. Cary, NC: SAS Institute, 2006
34. Salem RM, Pandey B, RichardEet al.Analysis oflongitudinal clinical information in genetics studies: structured and unstructured measurement patterns. J Health Services Res Policy. Forthcoming 2009
35. Wolfinger RD.Anexampleofusingmixed models and PROCMIXED for longitudinal data. J Biopharm Stat 1997; 7: 481-500
36. Littell RC, Pendergast J, Natarajan R. Modelling covariance structure in the analysis of repeated measures data. Stat Med 2000; 19: 1793-1819
37. Holden JE, Kelley K, Agarwal R. Analyzing change: a primer on multilevel models with applications to nephrology. Am J Nephrol 2008; 28: 792-801
38. Denison DGT, Mallick BK, Smith AFM. Bayesian MARS. Stat Com-put 1998; V8: 337-346
39. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics 2000; 1: 465-480
40. Faul F, Erdfelder E, Lang AG et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175-191
41. Halperin E, Eskin E. Haplotype reconstruction from genotype data using Imperfect Phylogeny. Bioinformatics 2004; 20: 1842-1849 (Pubitemid 39199048)
42. KanayamaN,Tsujimura R, She L et al. Cold-induced stress stimulates the sympathetic nervous system, causing hypertension and proteinuria in rats. J Hypertens 1997; 15: 383-389
43. King SE, Baldwin DS. Production of renal ischemia and proteinuria in man by the adrenal medullary hormones. Am J Med 1956; 20: 217-224
44. Light KC, Obrist PA, Sherwood A et al. Effects of race and marginally elevated blood pressure on responses to stress. Hypertension 1987; 10: 555-563
45. Insel PA, Snavely MD. Catecholamines and the kidney: receptors and renal function. Annu Rev Physiol 1981; 43: 625-636
46. Muhlbauer B, Spohr F, Schmidt R et al. Role of renal nerves and endogenous dopamine in amino acid-induced glomerular hyperfiltra-tion. Am J Physiol 1997; 273(Pt 2): F144-F149
47. O'Connor DT, Tyrell EA, Kailasam MT et al. Early alteration in glomerular reserve in humans at genetic risk of essential hypertension: mechanisms and consequences. Hypertension 2001; 37: 898-906
48. Boivin V, Jahns R, Gambaryan S et al. Immunofluorescent imaging of beta 1-and beta 2-adrenergic receptors in rat kidney. Kidney Int 2001; 59: 515-531
49. Anderson S, Brenner BM. Intraglomerular hypertension: implications and drug treatment. Annu Rev Med 1988; 39: 243-253
50. Green SA, Turki J, Innis M et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33: 9414-9419
51. Sandilands A, Yeo G, Brown MJ et al. Functional responses of human beta-1 adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms. Pharmacogenetics 2004; 14: 343-349
52. Rathz DA, Brown KM, Kramer LA et al. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 2002; 39: 155-160
53. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. F A S E B J 1990; 4: 2881-2889
54. Levin MC, Marullo S, Muntaner O et al. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 2002; 277: 30429-30435
55. Terra SG, Hamilton KK, Pauly DF et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 2005; 15: 227-234
56. Magnusson Y, Levin MC, Eggertsen R et al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 2005; 78: 221-231
57. Sehnert AJ, Daniels SE, Elashoff M et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 2008; 52: 644-651
58. Ranade K, Jorgenson E, Sheu WH et al. A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet 2002; 70: 935-942
59. Bengtsson K, Melander O, Orho-Melander M et al. Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation 2001; 104: 187-190
60. Liu J, Liu ZQ, Yu BN et al. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 2006; 80: 23-32
61. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77: 75-197
62. Kim SM, Chen L, Faulhaber-Walter R et al. Regulation of renin secretion and expression in mice deficient in beta1-and beta2-adrenergic receptors. Hypertension 2007; 50: 103-109
63. Peterson JC, Adler S, Burkart JM et al. The Modification of Diet in Renal Disease Study. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995; 123: 754-762
64. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892
65. Kunz R. Randomized trials and observational studies: still mostly similar results, still crucial differences. J Clin Epidemiol 2008; 61: 207-208